Milrinone in status asthmaticus

The use of Milrinone versus conventional treatment for the management of life-threatening bronchial asthma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201802002998973

Enrollment

Registered

2018-01-21

Start date

2017-10-02

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory bronchial asthma

Interventions

milrinone

control group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients ranging age 18-50 years old arriving at the emergency room with life-threatening asthma according to the criteria of the British Guideline on the management of asthma 2008, revised October 2014. Life-threatening asthma is defined as any one or more of the following criteria: ¿ PEF <33% best or predicted ¿ SpO2 <92% ¿ PaO2 <8 kPa (60 mm Hg) ¿ Normal PaCO2 (4.6-6.0 kPa) (35-45 mm Hg) ¿ Silent chest ¿ Cyanosis ¿ Poor respiratory effort ¿ Arrhythmia ¿ Exhaustion, altered conscious level ¿ Hypotension

Exclusion criteria

Exclusion criteria: ¿ patientes with pre-existing heart failure, hypotensive patients, stenotic or obstructive valvular disease or other outlet obstruction, and patients with pre-existing arrhythmia

Design outcomes

Primary

Measure	Time frame
assess the effectiveness of using milrinone as a rescue drug in life-threatening bronchial asthma	—

Secondary

Measure	Time frame
reducing the number of patients requiring mechanical ventilation.	—

Countries

Egypt

Contacts

Public Contactsahar kandil

associate profossor

saharkandil262@gmail.com20201224898998

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026